UltraSight raises $24 million to tackle shortage of cardiac imaging specialists
The Israeli startup’s AI platform enables trained medical staff to perform echocardiograms and is already installed in intensive care units at more than 10 medical facilities.
Rehovot-based medtech startup UltraSight has raised $24 million to expand the use of AI-powered echocardiography in U.S. healthcare systems, targeting a longstanding bottleneck in cardiac imaging: a shortage of trained specialists who can perform and interpret ultrasound examinations.
The round was led by Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations and eHealth Ventures, as well as existing investors including Mayo Clinic Ventures, NYU and Iron Nation. The financing brings UltraSight’s total capital raised since its founding to $42 million.
UltraSight has developed an AI-based platform designed to enable appropriately trained medical staff to perform echocardiograms, potentially allowing hospitals to expand access to cardiac imaging without relying exclusively on specialized sonographers.
The company says its approach can help hospitals improve patient flow, reduce waiting times and make more efficient use of medical staff. Its UltraSight Echosystem is currently installed in intensive care units at more than 10 medical facilities.
The need for such systems comes as demand for cardiac examinations continues to rise while hospitals face persistent shortages of skilled personnel. The resulting workload can delay access to imaging and, in turn, clinical decision-making.
UltraSight was founded in 2018 by Itay Kezurer (CTO), Prof. Yaron Lipman (Chief Scientific Officer), and Dr. Achiau Ludomirsky (CMO). Davidi Vortman is the company’s CEO.
The company currently employs 25 people, including 19 in Israel and the remainder in the U.S.
UltraSight plans to use the new funding to expand its commercial operations and implementation within U.S. healthcare systems. It will also continue developing clinical applications for intensive care units, where rapid access to cardiac imaging can directly affect treatment decisions.
Alongside the financing, Rick Geoffrion is joining UltraSight as chairman of the board. Geoffrion has more than 30 years of experience in the cardiovascular device industry, including work spanning interventional cardiology, circulatory support, structural heart disease and medical technology commercialization.
